<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00402935</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU3803</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-CWRU-3803</secondary_id>
    <secondary_id>CASE-01-04-15</secondary_id>
    <nct_id>NCT00402935</nct_id>
  </id_info>
  <brief_title>Ovarian Damage in Young Premenopausal Women Undergoing Chemotherapy for Cancer</brief_title>
  <official_title>Effects of Cytotoxic Chemotherapy on Ovarian Structure and Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Comparing results of diagnostic procedures, such as ultrasound, done before,
      during, and after chemotherapy may help doctors learn about the side effects of chemotherapy
      and help plan the best treatment.

      PURPOSE: This clinical trial is studying ovarian damage in young premenopausal women
      undergoing chemotherapy for cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the incidence and timing of ovarian dysfunction/damage in younger
           premenopausal women undergoing cytotoxic chemotherapy for cancer.

        -  Determine the feasibility of a prospective, randomized study to assess if gonadotropin
           analogues can protect the ovary from the cytotoxic effects of chemotherapy.

        -  Determine the number of patients required for adequate power to test the hypothesis.

      OUTLINE: This is a pilot, prospective study.

      Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume
      and count the number of antral follicles at baseline, 3 months after beginning cytotoxic
      chemotherapy, and at 6 months after completion of treatment. Patients undergo blood
      collection at the same time points for follicle-stimulating hormone, estradiol, and inhibin B
      levels. Patients are also asked to fill out questionnaires on estrogen-depletion symptoms at
      those times. Patients also keep a calendar of menstrual bleeding and hormonal medications.

      PROJECTED ACCRUAL: A total of 22 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    slow accrual
  </why_stopped>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of ovarian damage after cytotoxic chemotherapy as determined by changes in ovarian volume, antral follicle count, and follicle-stimulating hormone, estradiol, and inhibin B levels</measure>
    <time_frame>Ultrasound to measure the ovarian volume and count the number of antral follicles at baseline, 3 months after beginning cytotoxic chemotherapy, and at 6 months after completion of treatment. Patients undergo blood collection at the same time points.</time_frame>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Leukemia</condition>
  <condition>Long-term Effects Secondary to Cancer Therapy in Adults</condition>
  <condition>Long-term Effects Secondary to Cancer Therapy in Children</condition>
  <condition>Lymphoma</condition>
  <condition>Sexual Dysfunction and Infertility</condition>
  <condition>Sexuality and Reproductive Issues</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Patients undergo blood collection at the same time points for follicle-stimulating hormone, estradiol, and inhibin B levels.</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>fertility assessment and management</intervention_name>
    <description>Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles.</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>management of therapy complications</intervention_name>
    <description>Patients are also asked to fill out questionnaires on estrogen-depletion symptoms at those times. Patients also keep a calendar of menstrual bleeding and hormonal medications.</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ultrasound imaging</intervention_name>
    <description>Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles.</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood collection at the same time points for follicle-stimulating hormone, estradiol, and
      inhibin B levels.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        premenopausal women undergoing chemotherapy for cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of cancer, including, but not limited to, any of the following:

               -  Acute lymphocytic leukemia

               -  Acute myeloid leukemia

               -  Hodgkin's lymphoma

          -  Must have primary disease with significant chance for long-term survival after therapy

          -  Scheduled to receive chemotherapeutic agents known to be associated with ovarian
             failure, including any of the following:

               -  Cyclophosphamide

               -  Mechlorethamine hydrochloride

               -  Busulfan

               -  Procarbazine hydrochloride

               -  Chlorambucil

               -  Melphalan

               -  Ifosfamide

               -  Cisplatin

               -  Carboplatin

          -  Postmenarchal and premenopausal

        PATIENT CHARACTERISTICS:

          -  Female

          -  Weight ≤ 250 pounds

          -  Not pregnant

        PRIOR CONCURRENT THERAPY:

          -  No prior or concurrent total-body irradiation or radiotherapy to the pelvis

          -  Concurrent bone marrow transplantation allowed

          -  Concurrent oral contraception and/or gonadotropin releasing-hormone analogue allowed
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marjorie Greenfield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.gov/ct2/show/NCT00402935?term=cwru3803&amp;rank=1</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQ® database</description>
  </link>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2006</study_first_submitted>
  <study_first_submitted_qc>November 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2006</study_first_posted>
  <last_update_submitted>March 16, 2012</last_update_submitted>
  <last_update_submitted_qc>March 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2012</last_update_posted>
  <responsible_party>
    <name_title>Marjorie Greenfield, MD</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>long-term effects secondary to cancer therapy in adults</keyword>
  <keyword>long-term effects secondary to cancer therapy in children</keyword>
  <keyword>sexual dysfunction and infertility</keyword>
  <keyword>sexuality and reproductive issues</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>untreated adult acute lymphoblastic leukemia</keyword>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>untreated childhood acute myeloid leukemia and other myeloid malignancies</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>stage I adult Hodgkin lymphoma</keyword>
  <keyword>stage I childhood Hodgkin lymphoma</keyword>
  <keyword>stage II adult Hodgkin lymphoma</keyword>
  <keyword>stage II childhood Hodgkin lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage III childhood Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>stage IV childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

